The first Favipiravir-based drug in the world approved for the treatment of COVID-19
Research and development of medicines
Development and introduction in manufacture of innovative and reproduced synthetic and biotechnological Medicinal products "on a turn-key basis"
Investment activities
Investing in the development of innovative drugs; joint development of the projects of the ChemRar portfolio on partner terms; licensing and transfer of rights to the results of intellectual activity

«ChemRar» High-Tech center:

We develop and manufacture effective, safe and affordable medicines for the treatment of socially significant diseases and improvement of the quality of life:

• Using experience and global standards at all stages of creation of a novel medicine;

• Contributing to the development of the scientific and technological potential of the pharmaceutical industry in Russia;

• Applying our knowledge to search for optimal solutions for our partners.


The high efficacy of Avifavir®, the first registered drug for the treatment of COVID-19, in clinical practice was recognized at the All-Russian Congress on Infectious Diseases. Last week saw the closing of the 13th All-Russian Congress on Infectious Diseases named after academician V.I. Pokrovsky “Infectious Diseases in the Modern World: Current ...

Indonesia registers Russian drug with proven clinical efficacy against coronavirus Avifavir was the first Favipiravir-based drug in the world approved for the treatment of coronavirus and the first drug registered in Russia to treat coronavirus Moscow, March 24, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) ...

Chromis (Russia), a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF), and its partner Viriom Inc., a San Diego CA-based biotech reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic ...

The results of the two phases of the clinical trial of Avifavir for coronavirus treatment were presented at the “COVID-19: Pandemic of the XXI Century” International Congress held in Ufa on November 13–14. More than 3,500 experts from 8 countries (Russia, China, USA, Germany, Uzbekistan, Kazakhstan, Tajikistan, and Ukraine) took part in the ...

all news
Do you want to be aware of pharmaceutical news?
Subscribe to the weekly newsletter.

    I agree to the processing of personal data. Privacy policy